AMPH

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: PFE JNJ BMY LLY ABBV MRK REGN AZN GILD VRTX

| Held by: IJR VTI IWM VXF SPSM AVUV IWN PJP DFAT IJT

Index	RUT	P/E	11.55	EPS (ttm)	2.26	Insider Own	26.39%	Shs Outstand	46.35M	Perf Week	8.45%
Market Cap	1.20B	Forward P/E	7.07	EPS next Y	3.69	Insider Trans	-0.02%	Shs Float	33.41M	Perf Month	12.23%
Enterprise Value	1.58B	PEG	18.64	EPS next Q	0.92	Inst Own	71.55%	Short Float	12.55%	Perf Quarter	-12.43%
Income	111.63M	P/S	1.66	EPS this Y	-13.26%	Inst Trans	-0.01%	Short Ratio	9.39	Perf Half Y	4.83%
Sales	723.30M	P/B	1.56	EPS next Y	10.11%	ROA	6.95%	Short Interest	4.19M	Perf YTD	-29.81%
Book/sh	16.76	P/C	4.30	EPS next 5Y	0.62%	ROE	14.84%	52W High	46.43 -43.88%	Perf Year	-45.38%
Cash/sh	6.06	P/FCF	10.57	EPS past 3/5Y	34.92% 25.59%	ROIC	7.83%	52W Low	20.39 27.84%	Perf 3Y	-7.78%
Dividend Est.	-	EV/EBITDA	7.44	Sales past 3/5Y	18.69% 17.82%	Gross Margin	47.42%	Volatility	9.43% 4.64%	Perf 5Y	37.09%
Dividend TTM	-	EV/Sales	2.18	EPS Y/Y TTM	-27.66%	Oper. Margin	20.73%	ATR (14)	1.23	Perf 10Y	101.70%
Dividend Ex-Date	-	Quick Ratio	2.21	Sales Y/Y TTM	-0.03%	Profit Margin	15.43%	RSI (14)	53.53	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.12	EPS Q/Q	-53.32%	SMA20	3.82%	Beta	0.91	Target Price	32.00
Payout	0.00%	Debt/Eq	0.85	Sales Q/Q	0.33%	SMA50	0.55%	Rel Volume	0.66	Prev Close	26.37
Employees	2028	LT Debt/Eq	0.83	Earnings	Nov 06 AMC	SMA200	-0.57%	Avg Volume	446.58K	Price	26.06
IPO	Jun 25, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.69% 3.02%	Trades		Volume	294,067	Change	-1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-25	Upgrade	Needham	Hold → Buy	$36
May-12-25	Downgrade	JP Morgan	Overweight → Neutral	$30
Feb-04-25	Downgrade	Piper Sandler	Overweight → Neutral	$66 → $36
Nov-22-24	Initiated	Wells Fargo	Equal Weight	$55
Mar-05-24	Initiated	JP Morgan	Overweight	$60
Nov-17-23	Initiated	BofA Securities	Neutral	$63
Jul-25-23	Resumed	Jefferies	Buy	$70
Oct-21-22	Resumed	Jefferies	Buy	$36
Jul-29-22	Initiated	CapitalOne	Overweight	$44
Jan-07-22	Upgrade	Piper Sandler	Neutral → Overweight	$21 → $28
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$21
Oct-05-20	Upgrade	Northland Capital	Market Perform → Outperform	$24
May-01-20	Initiated	Northland Capital	Outperform	$23
Mar-13-19	Downgrade	Piper Jaffray	Overweight → Neutral	$24 → $23
Mar-13-19	Downgrade	Needham	Buy → Hold
Aug-10-18	Reiterated	Needham	Buy	$24 → $22
Mar-13-18	Reiterated	Needham	Buy	$23 → $24
Dec-01-17	Reiterated	Needham	Buy	$20 → $23
Nov-09-17	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-27-17	Reiterated	Needham	Buy	$18 → $20

Show Previous Ratings

Nov-13-25 12:34AM	5 Must-Read Analyst Questions From Amphastar Pharmaceuticals's Q3 Earnings Call (StockStory) -5.25%
Nov-12-25 03:20PM	Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today (StockStory)
06:00AM	Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (ACCESSWIRE)
Nov-11-25 10:31PM	Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best (StockStory)
Nov-10-25 03:21PM	Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today (StockStory) +8.70%
10:31AM	Loading…
10:31AM	AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures (StockStory)
Nov-07-25 10:01PM	Amphastar Pharmaceuticals Inc (AMPH) Q3 2025 Earnings Call Highlights: Strong Core Product ... (GuruFocus.com)
01:11PM	Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today (StockStory)
Nov-06-25 06:30PM	Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings (Zacks)
05:55PM	Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates (Zacks)
05:09PM	Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers (StockStory)
04:55PM	Amphastar: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 (ACCESSWIRE)
Nov-04-25 10:10PM	Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
05:30PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
10:00AM	Loading…
Oct-30-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:40AM	Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report? (Zacks)
Oct-27-25 06:00AM	Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025 (ACCESSWIRE)
12:01AM	2 Reasons AMPH is Risky and 1 Stock to Buy Instead (StockStory)
Oct-20-25 10:10AM	How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results? (Zacks)
Oct-17-25 09:40AM	Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? (Zacks)
09:35AM	Down 15.4% in 4 Weeks, Here's Why Amphastar (AMPH) Looks Ripe for a Turnaround (Zacks)
Oct-14-25 10:38AM	CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip? (Zacks)
Oct-07-25 10:32AM	Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? (Zacks)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-18-25 10:54AM	Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification? (Zacks)
Sep-15-25 10:27AM	CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? (Zacks)
Sep-04-25 11:32PM	A Look Back at Generic Pharmaceuticals Stocks' Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack (StockStory)
Sep-02-25 10:18AM	Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path? (Zacks)
08:46AM	Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock? (Zacks)
04:06AM	Loading…
04:06AM	Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection (Insider Monkey)
Aug-28-25 06:00AM	Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference (ACCESSWIRE)
Aug-14-25 01:42AM	05 Insightful Analyst Questions From Amphastar Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-13-25 07:33AM	Amphastar and Anji make licence agreement for three new peptides (Pharmaceutical Technology)
Aug-12-25 02:20PM	Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know (StockStory) +10.93%
01:38PM	Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum (Benzinga)
06:00AM	Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. (ACCESSWIRE)
03:25AM	AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones (StockStory)
Aug-11-25 12:31PM	Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today (StockStory) +14.91%
06:00AM	Amphastar Announces FDA Approval for Iron Sucrose Injection, USP (ACCESSWIRE)
Aug-08-25 11:00PM	Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... (GuruFocus.com) +10.13%
09:40AM	Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? (Zacks)
04:57AM	Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6% (StockStory)
Aug-07-25 05:30PM	Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:17PM	Amphastar: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 (ACCESSWIRE)
Aug-05-25 11:19PM	Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-04-25 10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 08:25PM	Bausch Health (BHC) Lags Q2 Earnings Estimates (Zacks)
Jul-29-25 06:00AM	Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025 (ACCESSWIRE)
Jul-23-25 12:00PM	What Makes Amphastar (AMPH) a New Buy Stock (Zacks) +6.00%
09:40AM	Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? (Zacks)
09:35AM	Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks (Zacks)
Jul-14-25 04:05PM	Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters (ACCESSWIRE)
Jul-10-25 11:14AM	JPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral from Overweight, Brings PT Down to $30 (Insider Monkey)
Jul-04-25 01:35AM	Amphastar Pharmaceuticals's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Jun-25-25 12:01AM	Amphastar Pharmaceuticals (AMPH): Buy, Sell, or Hold Post Q1 Earnings? (StockStory)
Jun-11-25 09:25AM	AMPH Q1 Earnings Call: Product Mix Shift and Margin Pressures Highlight Competitive Challenges (StockStory)
May-22-25 11:36PM	Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers (StockStory)
06:00AM	Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (ACCESSWIRE)
May-09-25 06:00AM	Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference (ACCESSWIRE)
May-08-25 10:49AM	Q1 2025 Amphastar Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-07-25 07:30PM	Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics (Zacks)
07:22PM	Amphastar outlines key launches and product growth drivers for 2025 (Seeking Alpha)
07:20PM	Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates (Zacks)
04:32PM	Amphastar: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 (ACCESSWIRE)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
May-06-25 05:30PM	Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-01-25 03:06PM	Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? (Zacks)
Apr-30-25 06:00AM	Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025 (ACCESSWIRE)
Apr-29-25 09:00AM	2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of (StockStory)
Apr-28-25 05:05AM	Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest (StockStory)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-15-25 01:45PM	Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth? (Insider Monkey)
05:06AM	2 Reasons to Like AMPH and 1 to Stay Skeptical (StockStory)
Apr-03-25 06:00AM	Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (ACCESSWIRE)
Mar-28-25 06:00AM	International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award (ACCESSWIRE)
Mar-24-25 05:29AM	New Strong Sell Stocks for March 24th (Zacks)
Mar-13-25 05:01AM	Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Mar-05-25 06:00AM	Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference (ACCESSWIRE)
04:03AM	Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers (StockStory)
Mar-01-25 07:27AM	Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Small Cap Pharma Stocks to Buy Now? (Insider Monkey)
Feb-28-25 02:15PM	Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds (Benzinga) -9.72%
12:01PM	Amphastar Pharmaceuticals Inc (AMPH) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Feb-27-25 06:30PM	Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates (Zacks)
05:23PM	Amphastar: Q4 Earnings Snapshot (Associated Press Finance)
05:02PM	Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1% (StockStory)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024 (ACCESSWIRE)
Feb-26-25 08:17AM	Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow (StockStory)
07:42AM	Amphastar Pharmaceuticals Inc (AMPH) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-21-25 04:07AM	Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Feb-20-25 04:05PM	Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025 (ACCESSWIRE)
Feb-19-25 04:01AM	Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest (StockStory)
Feb-14-25 04:01AM	Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Floyd Petersen	Director	Nov 13 '25	Proposed Sale	26.49	16,679	441,837		Nov 13 05:06 PM
Petersen Floyd F.	Director	Nov 03 '25	Sale	25.27	500	12,633	75,531	Nov 05 04:20 PM
Petersen Floyd F.	Director	Nov 03 '25	Proposed Sale	25.30	500	12,650		Nov 03 04:24 PM
Petersen Floyd F.	Director	Oct 01 '25	Sale	27.20	500	13,602	76,031	Oct 02 05:04 PM
Petersen Floyd F.	Director	Oct 01 '25	Proposed Sale	26.74	500	13,370		Oct 01 04:07 PM
Petersen Floyd F.	Director	Sep 02 '25	Sale	30.98	500	15,492	76,531	Sep 03 04:20 PM
Petersen Floyd F.	Director	Sep 02 '25	Proposed Sale	30.90	500	15,450		Sep 02 04:08 PM
Petersen Floyd F.	Director	Aug 01 '25	Sale	20.83	500	10,416	77,031	Aug 04 07:17 PM
Petersen Floyd F.	Director	Aug 01 '25	Proposed Sale	20.86	500	10,430		Aug 01 04:08 PM
Petersen Floyd F.	Director	Jul 02 '25	Sale	23.47	500	11,734	77,531	Jul 03 05:30 PM
Petersen Floyd F.	Director	Jul 02 '25	Proposed Sale	23.43	500	11,715		Jul 02 04:01 PM
Zhang Jack Y.	CEO & CHIEF SCIENTIFIC OFFICER	Jun 13 '25	Option Exercise	13.03	200,000	2,606,000	2,847,659	Jun 16 05:19 PM
Petersen Floyd F.	Director	Jun 02 '25	Sale	25.67	500	12,835	72,909	Jun 04 06:39 PM
Petersen Floyd F.	Director	Jun 02 '25	Proposed Sale	25.61	500	12,805		Jun 02 04:06 PM
Petersen Floyd F.	Director	May 01 '25	Sale	24.08	500	12,041	73,409	May 02 08:27 PM
Petersen Floyd F.	Director	May 01 '25	Proposed Sale	24.19	500	12,095		May 01 04:03 PM
Petersen Floyd F.	Director	Apr 01 '25	Sale	28.38	500	14,190	73,909	Apr 02 06:45 PM
Petersen Floyd F.	Director	Apr 01 '25	Proposed Sale	28.86	500	14,430		Apr 01 04:01 PM
Zhang Jack Y.	CEO & CHIEF SCIENTIFIC OFFICER	Mar 14 '25	Option Exercise	14.69	290,477	4,267,107	2,899,859	Mar 18 07:13 PM
Zhang Jack Y.	CEO & CHIEF SCIENTIFIC OFFICER	Mar 14 '25	Option Exercise	14.69	211,213	3,102,719	1,359,470	Mar 18 07:13 PM
Petersen Floyd F.	Director	Mar 06 '25	Sale	27.99	1,000	27,986	74,409	Mar 07 04:01 PM
PETERS WILLIAM J	CFO, EVP & TREASURER	Mar 04 '25	Option Exercise	13.35	7,490	99,992	101,594	Mar 06 05:00 PM
PETERS WILLIAM J	CFO, EVP & TREASURER	Mar 04 '25	Sale	27.54	4,231	116,515	97,363	Mar 06 05:00 PM
Petersen Floyd F.	Director	Mar 06 '25	Proposed Sale	27.80	1,000	27,800		Mar 06 04:02 PM
PETERS WILLIAM J	Officer	Mar 04 '25	Proposed Sale	27.21	4,231	115,126		Mar 04 04:07 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Dec 13 '24	Option Exercise	11.33	8,000	90,640	126,469	Dec 16 05:22 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Dec 12 '24	Option Exercise	11.33	7,000	79,310	125,469	Dec 16 05:22 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Dec 13 '24	Sale	45.23	8,000	361,840	118,469	Dec 16 05:22 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Dec 12 '24	Sale	44.42	7,000	310,975	118,469	Dec 16 05:22 PM
PRINS RICHARD K	Director	Dec 09 '24	Option Exercise	19.52	10,000	195,200	40,471	Dec 11 08:28 PM
PRINS RICHARD K	Director	Dec 09 '24	Sale	43.77	10,000	437,702	30,471	Dec 11 08:28 PM
Richard Prins	Executive	Dec 09 '24	Proposed Sale	44.00	10,000	440,000		Dec 09 11:37 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Amphastar Pharmaceuticals Inc

Upgrade your FINVIZ experience